ArticlePloS one2025
Multi-channel pricing strategies for pharmaceutical supply chains considering channel power and price competition.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the context of the reality that pharmaceutical manufacturers and retailers are simultaneously opening online sales channels, three different multi-channel pharmaceutical supply chain game models were constructed based on game theory, considering channel power, triple price competition among channels, and health insurance reimbursement policies, among others, comparing and analyzing the effects of each influencing factor on pharmaceutical pricing and profits in the pharmaceutical supply chain. It was found that inter-channel price competition did not always reduce the prices of a retailer's pharmaceuticals; price competition between physical retail channels and online retail channels could lead to higher pharmaceutical prices, but direct sales channels effectively reduced pharmaceutical prices. Furthermore, as the channel power of pharmaceutical retailers strengthens, retail prices will increase, and retailers' profits will rise. However, as the channel power of pharmaceutical manufacturers increases, their profits will grow, but retail prices will correspondingly decrease. Appropriate increasing in the health insurance reimbursement rate could improve pharmaceutical pricing in each channel and the total profits of the pharmaceutical supply chains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.